PharmAsia News Notable Notes: WuXi Confronts Chinese Macro Challenges
This article was originally published in PharmAsia News
Executive Summary
WuXi Pharma has systems in place to soften the impact of cost inflation issues expected to impact the Chinese pharma industry, according to Oppenheimer analyst Charles Rhyee
You may also be interested in...
WuXi Apptec Plots Future, But Is It Overreaching?
WASHINGTON - WuXi Apptec CEO Ge Li believes the company will benefit greatly from ramping up capability and capacity to meet growing demand, but analysts question whether the increased capacity will be fully utilized
WuXi Apptec Plots Future, But Is It Overreaching?
WASHINGTON - WuXi Apptec CEO Ge Li believes the company will benefit greatly from ramping up capability and capacity to meet growing demand, but analysts question whether the increased capacity will be fully utilized
While Navigating Risks, WuXi To Benefit from Global Outsourcing
BEIJING - WuXi PharmaTech is positioning itself to ride the rising tides of global pharmaceutical outsourcing to strengthen its role as China's largest contract research organization, according to a WuXi executive and an independent analyst